FAK activation was only partially blocked by Dasatinib (ranging from 40–60%) while Src activation was completely blocked at the same dose (such as 10 nM) (Fig. 5A), suggesting that in pancreatic cancer cells FAK activation is not totally dependent upon Src. This evidence concerns the gene PTK2 and familial pancreatic carcinoma.